Status:
TERMINATED
A Study Of The Safety And Efficacy Of AG-013,958 In Subjects With Subfoveal Choroidal Neovascularization Associated With Age-Related Macular Degeneration
Lead Sponsor:
Pfizer
Conditions:
Age-Related Macular Degeneration
Eligibility:
All Genders
55+ years
Phase:
PHASE1
PHASE2
Brief Summary
AG-013,958 is being studied to treat patients with Age-Related Macular Degeneration. A total of 144 subjects may be enrolled in the trial. Subjects will be male or female at least 55 years of age with...
Eligibility Criteria
Inclusion
- Male and/or female subjects \>=55 years of age
- Subfoveal choroidal neovascularization complicating age-related macular degeneration
- Subjects who are informed of, and willing and able to comply with, the investigational nature of the study and are able to provide written informed consent in accordance with institutional and regulatory guidelines
Exclusion
- Other serious ocular diseases or conditions, including diabetic retinopathy and glaucoma, that are likely to compromise visual acuity within 1 year
Key Trial Info
Start Date :
January 1 2004
Trial Type :
INTERVENTIONAL
End Date :
August 1 2006
Estimated Enrollment :
155 Patients enrolled
Trial Details
Trial ID
NCT00090532
Start Date
January 1 2004
End Date
August 1 2006
Last Update
May 27 2011
Active Locations (39)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Mesa, Arizona, United States
2
Pfizer Investigational Site
Oro Valley, Arizona, United States
3
Pfizer Investigational Site
Phoenix, Arizona, United States
4
Pfizer Investigational Site
Sun City, Arizona, United States